Home > List of Issue > Table of Contents > Abstract

Journal of Nippon Medical School

Full Text of this Article

-Original-

Altered Microglia in the Amygdala Are Involved in Anxiety-related Behaviors of a Copy Number Variation Mouse Model of Autism

Tomoko Shigemori1,2, Atsushi Sakai1, Toru Takumi3, Yasuhiko Itoh2 and Hidenori Suzuki1

1Department of Pharmacology, Nippon Medical School
2Department of Pediatrics, Nippon Medical School
3RIKEN Brain Science Institute


Background and Purpose: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a strong genetic basis. Although anxiety is a common major psychiatric condition in ASD, the underlying mechanisms of the anxiety are poorly understood. In individuals with ASD, evidence indicates a structural abnormality in the amygdala, a key component involved in anxiety and social behavior. Microglia, which are central nervous system-resident immune cells implicated in neurodevelopmental processes, are also reportedly altered in ASD. In the present study, we examined the involvement of microglia in the anxiety-related behaviors of ASD model mouse.
Methods: Mice that have a 6.3-Mb paternal duplication (patDp/+) corresponding to human chromosome 15q11-q13 were used as an ASD model. Iba1, a microglial activation marker, was examined in the amygdala using immunofluorescence. Effects of perinatal treatment with minocycline, a microglial modulator, on anxiety-related behaviors were examined in neonatal and adolescent patDp/+ mice.
Results: In patDp/+ mice, Iba1 was decreased in the basolateral amygdala at postnatal day 7, but not at postnatal days 37-40. Perinatal treatment with minocycline restored the Iba1 expression and reduced anxiety-related behaviors in patDp/+ adolescent mice.
Conclusions: Perinatal microglia in the basolateral amygdala may play a pathogenic role in the anxiety observed in a mouse model of ASD with duplication of human chromosome 15q11-q13.

J Nippon Med Sch 2015; 82: 92-99

Keywords
amygdala, anxiety, autism spectrum disorder, microglia, minocycline

Correspondence to
Hidenori Suzuki, MD, PhD, Department of Pharmacology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan
hsuzuki@nms.ac.jp

Received, December 22, 2014
Accepted, January 6, 2015